Legal
A three-judge panel ruled against Shkreli’s appeals team, claiming that the trial judge’s directions were clear and within the law.
A federal judge ordered that information on sales of opioids up to the year 2013 could be released.
In November 2018, Chinese researcher He Jiankui announced he had used CRISPR gene editing to modify the CCR5 genes in the embryos of seven Chinese couples. This was met by widespread condemnation, investigations and a call for a global moratorium against that type of research.
The Sackler family has earned billions from the sale of OxyContin and the backlash against the family has increased in-fighting, according to reports.
Reckitt Benckiser spun Indivior off into a standalone company in 2014. Earlier this year the Department of Justice charged Indivior for its role in the opioid crisis.
According to a University College London (UCL) report, British researchers are being shut out of major European research partnerships because of concerns over a no-deal Brexit.
In addition to the states agreeing to pause lawsuits, the FDA accepted Insys’ NDA for an opioid overdose medication.
Four bills aimed at lowering prescription drug prices were advanced out of the U.S. Senate Judiciary Committee this week and will head to a vote on the Senate floor.
Allergy Therapeutics plc, the fully integrated commercial biotechnology company specialising in allergy vaccines, announces that it has received a $7.6m settlement from Inflamax Research Inc. in relation to legal proceedings about the previously disclosed inconclusive Phase II Grass MATA MPL trial which took place in the USA in 2015-16.
Allergy Therapeutics plc, the fully integrated commercial biotechnology company specialising in allergy vaccines, announces a pre-close trading update for the 12 months ended 30 June 2019 and the successful outcome of the litigation related to the Grass MATA MPL Phase II trial.
PRESS RELEASES